Sustainability
As a pharmaceutical and healthcare company, STADA is responsible for ensuring the group-wide safety of its products and thus also the safety of patients. That’s what SDG 17 is all about.
Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
Explore STADA
Your opportunity for success with STADA
We are looking for qualified employees who drive our company forward with their specialist knowledge and commitment. We offer appealing conditions with diverse and exciting tasks as well as good career prospects and a motivating working environment.
I am very pleased to welcome Ingo Schachel as STADA‘s Head of Investor Relations!
By Boris Döbler, CFO of STADA
What do you value most about our company culture?
By Simone Berger,
November 2024 concluded on a high note as I had the privilege of joining the STADAGroup Global Communication Core Team meeting ...
Minh Bui, Head of Public Affairs and Communications at
🌟 Kicking Off STADA's Reverse Mentoring Program in Hemofarm, Serbia! 🌟
By Tara Rodic,
Today, I had the privilege of participating in another great STADAUKConversation!
By Madison O’Reilly, HR Apprentice at Thornton & Ross
STADA Voices
Latest news
10/10/2024
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
26/07/2024
European Commission approval to expand label & patient group for IgA Nephropathy orphan medicine
24/06/2024
STADA Health Report 2024: Satisfaction with healthcare systems continues to decline
28/05/2024
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, EU and UK
21/05/2024
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
10/05/2024
Xbrane, STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US
10/01/2024
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
Meeting colleagues and leaders in person for the first time after nearly a year of remote interactions was an inspiring experience that reinforced the power of human connection. The two-day event was a dynamic exchange of ideas, strategies, and perspectives from across the Group and its affiliates, uniting us under the shared goal of driving impactful communication.
As someone committed to constant learning and growth, the case studies showcased by my colleagues were particularly enlightening – not as blueprints to replicate, but as sources of inspiration to innovate and adapt for Vietnam’s unique context.
This experience reaffirmed that collaboration and diverse perspectives fuel creativity and success. I’m energised and ready to bring these insights back home as we continue to amplify our communication efforts to promote the new corporate positioning and new identity of STADA Pymepharco in Vietnam and contribute to STADA Group’s vision.